奥希替尼对生物标志物表达的调节:AURA I期试验配对肿瘤活检队列结果
AURA I期试验配对肿瘤活检队列评估奥希替尼治疗后关键分子生物标志物的变化。61例EGFR T790M肿瘤患者采集基线活检,29例因肿瘤缩小或样本不足无法采集治疗后活检,24例可评估。无法采集治疗后活检的患者客观缓解率62%、中位无进展生存期9.7个月,优于配对活检可评估患者的29%和6.6个月。
要点
- 奥希替尼治疗后肿瘤快速缩小导致配对活检采集困难,29例无可行治疗后活检样本。
- 无法采集治疗后活检患者ORR 62%、mPFS 9.7个月,配对活检可评估患者ORR 29%、mPFS 6.6个月(p=0.027)。
- 奥希替尼调节关键EGFR信号通路并增加免疫细胞浸润。
核心结论
- 奥希替尼治疗后肿瘤快速缩小使配对活检采集具有挑战性,凸显了在接受高活性药物治疗的患者中进行研究期间活检的困难。
研究设计与样本
- I期AURA试验的配对肿瘤活检队列,在奥希替尼治疗前及治疗15±7天(每日80或160 mg)后采集配对肿瘤活检样本。
- 基线肿瘤活检样本来自61例EGFR T790M肿瘤患者,其中24例采集到可评估的治疗前和治疗后配对肿瘤活检样本。
- 免疫组化分析评估关键通路和肿瘤/免疫相关标志物(磷酸化EGFR、磷酸化S6、磷酸化AKT、程序性死亡配体1和CD8),样本由图像分析或对治疗分配设盲的病理学家评分。
主要发现
- 29例患者因肿瘤缩小或肿瘤样本不足而无可行的治疗后活检样本。
- 无法采集治疗后活检样本的患者客观缓解率为62%、中位无进展生存期为9.7个月(p=0.027),配对样本可采集患者客观缓解率为29%、中位无进展生存期为6.6个月。
- 奥希替尼调节关键EGFR信号通路并导致免疫细胞浸润增加。
局限性
- 由于奥希替尼治疗后肿瘤快速缩小,配对活检样本采集具有挑战性,凸显了在接受高活性药物治疗的患者中进行研究期间活检的困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib is an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR TKI and T790M resistance mutations. To enhance understanding of osimertinib's mechanism of action, we aimed to evaluate the modulation of key molecular biomarkers after osimertinib treatment in paired clinical samples from the phase I AURA trial. METHODS: Paired tumor biopsy samples were collected before the study and after 15 plus or minus 7 days of osimertinib treatment (80 or 160 mg daily). Clinical efficacy outcomes were assessed according to whether viable paired biopsy samples could be collected; safety was also assessed. Immunohistochemical analyses assessed key pathway and tumor/immune-relevant markers (phospho-EGFR, phospho-S6, phospho-AKT, programmed death ligand 1, and CD8), with samples scored by image analysis or a pathologist blinded to treatment allocation. RESULTS: Predose tumor biopsy samples were collected from 61 patients with EGFR T790M tumors; 29 patients had no viable postdose biopsy sample because of tumor regression or insufficient tumor sample. Evaluable predose and postdose tumor biopsy samples were collected from 24 patients. Objective response rate (ORR) and median progression-free survival (mPFS) were improved in patients from whom a postdose biopsy sample could not be collected (ORR 62% and mPFS 9.7 months [p = 0.027]) compared with those from whom paired samples were collected (ORR 29% and mPFS 6.6 months). Osimertinib modulated key EGFR signaling pathways and led to increased immune cell infiltration. CONCLUSIONS: Collection of paired biopsy samples was challenging because of rapid tumor regression after osimertinib treatment, highlighting the difficulties of performing on-study biopsies in patients treated with highly active drugs.
引用
- Thress KS, Jacobs V, Angell HK, et al. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017. PMID: 28751247. doi:10.1016/j.jtho.2017.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。